Jason Ylizarde is listed as an executive officer and director on 4 SEC Form D filings by 2 issuers between Mar 2022 and Jun 2025: Dragonfly Endoscopy Inc. (Englewood,, CO — other health care — 2022; $12.7M reported sold to 28 investors) and Origin Endoscopy Inc. (Englewood, CO — biotechnology — 2024–2025; $2.34M reported sold to 5 investors).
What this means 2 separate companies raised money with this person listed as executive officer and director, over about 3 years. Across those companies the filings report $15M sold in total.
Listed alongside Jeremy Starkweather (4 shared filings), John Wynne (4 shared filings), Jason Grimes (3 shared filings), Michael Freeman (3 shared filings) and Stephen Hoag (3 shared filings).
What this means These are the other officers, directors or promoters the companies named on the same forms — the team around Jason. Each name links to their own page.
All 2 issuers belong to the sponsor group Dragonfly (3 issuers, $16.5M reported sold, 2022–2025).
What this means A sponsor group is one team that sets up a new company for each deal. Dragonfly has 3 companies on file and $16.5M reported sold in total — the group page shows the whole track record in one place.
Public records searched: federal courts (CourtListener / RECAP), SEC enforcement releases, state securities regulators (AR, AZ, CA, CT, DE, FINRA, GA, HI, ID, LA, ME, MO, MS, MT, NASAA, NC, NH, NM, OR, RI, TX, WA) — none found.
What this means Nothing turned up where we looked (3 sources). That does not prove there is nothing — it means none was found in those sources on that date.
We compared 4 public filings for Jason Ylizarde and found 5 differences: Form D filed 17 days after the first sale; No amendment in the last 12 months on an offering that may still be open; and more below.
What this means These are differences between the sponsor's own SEC filings — both values, dates and sources are listed in Key records, section 4. Most have ordinary explanations; ask the sponsor.